Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2019

Open Access 01-12-2019 | Heart Failure | Original investigation

Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study

Authors: B. Zareini, Rasmus Rørth, Anders Holt, Ulrik M. Mogensen, Christian Selmer, Gunnar Gislason, Morten Schou, Lars Køber, Christian Torp-Pedersen, Morten Lamberts, Søren Lund Kristensen

Published in: Cardiovascular Diabetology | Issue 1/2019

Login to get access

Abstract

Background

Prevalent diabetes at the time of heart failure (HF) diagnosis is associated with a higher risk of death, but the incidence and prognostic importance of new-onset diabetes in patients with established HF remains unknown.

Methods

Patients with a first hospitalization for HF in the period 2003–2014 were included and stratified according to history of diabetes. Annual incidence rates of new-onset diabetes were calculated and time-dependent multivariable Cox regression models were used to compare the risk of death in patients with prevalent and new-onset diabetes with patients without diabetes as reference. The model was adjusted for age, sex, duration of HF, educational level and comorbidity. Covariates were continuously updated throughout follow-up.

Results

A total of 104,522 HF patients were included in the study, of which 21,216 (19%) patients had diabetes at baseline, and 8164 (10%) developed new-onset diabetes during a mean follow-up of 3.9 years. Patients with new-onset diabetes and prevalent diabetes were slightly younger than patients without diabetes (70 vs. 74 and 77, respectively), more likely to be men (62% vs. 60% and 54%), and had more comorbidities expect for ischemic heart disease, hypertension and chronic kidney disease which were more prevalent among patients with prevalent diabetes. Incidence rates of new-onset diabetes increased from around 2 per 100 person-years in the first years following HF hospitalization up to 3 per 100 person-years after 5 years of follow-up. A total of 61,424 (59%) patients died during the study period with event rates per 100 person-years of 21.5 for new-onset diabetes, 17.9 for prevalent diabetes and 13.9 for patients without diabetes. Compared to patients without diabetes, new-onset diabetes was associated with a higher risk of death (adjusted HR 1.47; 95% CI 1.42–1.52) and prevalent diabetes was associated with an intermediate risk (HR 1.19; 95% CI, 1.16–1.21).

Conclusion

Following the first HF hospitalization, the incidence of new-onset diabetes was around 2% per year, rising to 3% after 5 years of follow-up. New-onset diabetes was associated with an increased risk of death, compared to HF patients with prevalent diabetes (intermediate risk) and HF patients without diabetes.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Gerstein HC, Swedberg K, Carlsson J, et al. The hemoglobin a1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in heart failure: assessment of reduction in mortality and morbidity (charm) program. Arch Intern Med. 2008;168(15):1699–704. https://doi.org/10.1001/archinte.168.15.1699.CrossRefPubMed Gerstein HC, Swedberg K, Carlsson J, et al. The hemoglobin a1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in heart failure: assessment of reduction in mortality and morbidity (charm) program. Arch Intern Med. 2008;168(15):1699–704. https://​doi.​org/​10.​1001/​archinte.​168.​15.​1699.CrossRefPubMed
10.
go back to reference Kristensen JK, Drivsholm TB, Carstensen B, Steding-Jensen M, Green A. Validation of methods to identify known diabetes on the basis of health registers. Ugeskr Laeg. 2007;169(18):1687–92.PubMed Kristensen JK, Drivsholm TB, Carstensen B, Steding-Jensen M, Green A. Validation of methods to identify known diabetes on the basis of health registers. Ugeskr Laeg. 2007;169(18):1687–92.PubMed
14.
23.
go back to reference Preiss D, van Veldhuisen DJ, Sattar N, Krum H, Swedberg K, Shi H, et al. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail. 2012;14(8):909–15. https://doi.org/10.1093/eurjhf/hfs067.CrossRefPubMed Preiss D, van Veldhuisen DJ, Sattar N, Krum H, Swedberg K, Shi H, et al. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail. 2012;14(8):909–15. https://​doi.​org/​10.​1093/​eurjhf/​hfs067.CrossRefPubMed
24.
Metadata
Title
Heart failure and the prognostic impact and incidence of new-onset of diabetes mellitus: a nationwide cohort study
Authors
B. Zareini
Rasmus Rørth
Anders Holt
Ulrik M. Mogensen
Christian Selmer
Gunnar Gislason
Morten Schou
Lars Køber
Christian Torp-Pedersen
Morten Lamberts
Søren Lund Kristensen
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2019
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-019-0883-4

Other articles of this Issue 1/2019

Cardiovascular Diabetology 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.